Abstract
Lipid nanoparticles (LNPs) have emerged as a promising platform for targeted drug delivery in cancer therapy due to their biocompatibility, ability to encapsulate a wide range of therapeutic agents, and potential for enhancing the bioavailability and stability of drugs. LNPs are particularly valuable for the delivery of poorly soluble anticancer drugs, nucleic acids, and gene therapies. This article explores the role of lipid nanoparticles in cancer treatment, their mechanisms of action, and the ongoing advancements in their design and application. Challenges such as stability, scale-up production, and regulatory approval are also discussed. Furthermore, the future prospects for LNP-based cancer therapies are examined, highlighting the need for personalized approaches to optimize treatment outcomes.
All articles published in the American Journal of Pharmaceutics are open access and licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows users to:
-
Share — copy and redistribute the material in any medium or format
-
Adapt — remix, transform, and build upon the material for any purpose, even commercially
Under the following terms:
-
Attribution — Appropriate credit must be given, a link to the license must be provided, and any changes must be indicated.
-
Authors retain full copyright of their work.
-
The journal does not restrict reuse of content, provided proper citation of the original publication is made.